A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 14 Apr 2017
At a glance
- Drugs Neratinib (Primary) ; Trastuzumab emtansine
- Indications Adenocarcinoma; Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Apr 2017 According to a Puma Biotechnology media release, results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2017.
- 02 Apr 2017 Results published in the Puma Biotechnology media release.
- 01 Mar 2017 According to a Puma Biotechnology media release, data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History